Thursday, 19 March 2020, 14:15 HKT/SGT

Source: Eisai

TOKYO, Mar 19, 2020 - (JCN Newswire) - EA Pharma Co., Ltd. and its parent company Eisai Co., Ltd. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has given notification of the results of reexamination to the effect that the "all-case surveillance" specified drug use-results survey condition required for the approval of "Actonel 17.5 mg tablets" (risedronate sodium hydrate) indicated for the treatment of Paget's disease of bone has been lifted.

In July 2008, MHLW approved the indication for treatment of "Paget's disease of bone" for "Actonel 17.5 mg tablets" with the following conditions for approval: "Because of the very limited number of subjects treated in the Japanese clinical trials, the applicant is required to conduct all-case drug use-results survey until data from a certain number of patients are accumulated after market launch, in order to identify the background information of patients treated with the product and collect safety and efficacy data on the product in the early post-marketing period, and thereby take necessary measures to ensure proper use of the product."

Based on the safety data in 307 patients and efficacy data in 276 patients submitted to MHLW as the results of analyses of all-case surveillance, MHLW has concluded that the all-case surveillance was conducted properly and the necessary measures to ensure proper use of the product were being taken sufficiently to lift the condition.

EA Pharma Co., Ltd. and Eisai Co., Ltd. continually strive to promote proper use of the product and provide timely additional information of the product to increase benefits to patients and their families.

Contact:

EA Pharma Co., Ltd. 
Corporate Planning Dept. 
TEL: +81(0)3-6280-9802

Eisai Co., Ltd. 
Public Relations Dept. 
TEL: +81(0)3-3817-5120

Topic: Press release summary
Source: Eisai
Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network

Eisai

Dec 11, 2025 18:41 HKT/SGT

Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year

Dec 9, 2025 17:51 HKT/SGT

"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

Dec 4, 2025 17:36 HKT/SGT

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025

Dec 3, 2025 17:19 HKT/SGT

New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

Dec 2, 2025 23:01 HKT/SGT

Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025

Nov 28, 2025 22:00 HKT/SGT

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan

Nov 26, 2025 18:42 HKT/SGT

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Nov 17, 2025 21:08 HKT/SGT

"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom

Oct 30, 2025 13:43 HKT/SGT

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

Oct 28, 2025 23:30 HKT/SGT

Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

More news >>

News Alerts


Home \| About us \| Services \| Partners \| Events \| Login \| Contact us \| Privacy Policy \| Terms of Use \| RSS

US: +1 214 890 4418 \| China: +86 181 2376 3721 \| Hong Kong: +852 8192 4922 \| Singapore: +65 6549 7068 \| Tokyo: +81 3 6859 8575

Connect With us: